申请人:ICI Pharma
公开号:US05173496A1
公开(公告)日:1992-12-22
The invention concerns pharmaceutical compositions containing a 1,2-dihydro-3H-indazol-3-one derivative of the formula I ##STR1## wherein Ra is hydrogen, halogeno, nitro, hydroxy, (2-6C)alkanoyloxy, (1-6C)alkyl, (1-6C)alkoxy, fluoro-(1-4C)alkyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-4C)alkyl]amino, (2-6C)alkanoylamino or hydroxy-(1-6C)alkyl; Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; and Y is a group of the formula --A.sup.1 --X--A.sup.2 --Q in which A.sup.1 is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene, or A.sup.1 is phenylene; X is oxy, thio, sulphinyl, sulphonyl, imino, (1-6C)alkylimino, (1-6C)alkanoylimino, iminocarbonyl or phenylene, or X is a direct link to A.sup.2 ; A.sup.2 is (1-6C)alkylene, (3-6C)alkenylene or (3-6C)alkynylene or A.sup.2 is cyclo(3-6C)alkylene or is a direct link to Q, or the group --A.sup.1 --X--A.sup.2 -- is a direct link to Q; or Y is (2-10)alkyl, (3-10C)alkenyl or (3-6C)alkynyl; and Q is aryl or heteroaryl. The invention also provides novel 1,2-dihydro-3H-indazol-3-ones, processes for their production and the use of 1,2-dihydro-3H-indazol-3-ones for the manufacture of medicaments for the treatment of various allergic and inflammatory diseases.
该发明涉及含有式I的1,2-二氢-3H-吲唑-3-酮衍生物的药物组合物
其中Ra为氢,卤素,硝基,羟基,(2-6C)烷酰氧基,(1-6C)烷基,(1-6C)烷氧基,氟代(1-4C)烷基,(2-6C)烷酰基,氨基,(1-6C)烷基氨基,二-[(1-4C)烷基]氨基,(2-6C)烷酰氨基或羟基(1-6C)烷基;Rb为氢,卤素,(1-6C)烷基或(1-6C)烷氧基;Y为式--A.sup.1 --X--A.sup.2 --Q的基团,其中A.sup.1为(1-6C)烷基,(3-6C)烯基,(3-6C)炔基或环(3-6C)烷基,或A.sup.1为苯基;X为氧,硫,亚硫基,砜基,亚砜基,亚胺基,(1-6C)烷基亚胺基,(1-6C)烷酰亚胺基,亚氨基甲酰基或苯基,或X为与A.sup.2的直接连接;A.sup.2为(1-6C)烷基,(3-6C)烯基或(3-6C)炔基,或A.sup.2为环(3-6C)烷基或与Q的直接连接,或基团--A.sup.1 --X--A.sup.2 --为与Q的直接连接;或Y为(2-10)烷基,(3-10C)烯基或(3-6C)炔基;Q为芳基或杂芳基。该发明还提供了新型1,2-二氢-3H-吲唑-3-酮,其生产工艺以及用于制备治疗各种过敏和炎症性疾病药物的1,2-二氢-3H-吲唑-3-酮的用途。